In conclusion, our study has identified DUSP4 as the vital gene associated with Lenvatinib resistance in HCC by employing the genome-wide CRISPR/Cas9 library screening, which may provide an important reference for overcoming tyrosine kinase inhibitors resistance. This evidence concerns the gene DUSP4 and hepatocellular carcinoma.